InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (8 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
8
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Carter Percy H., Directeur Scientifique. Insider active across 1 company, notably Blueprint Medicines Corp. Cumulatively, 15 reports have been logged. Split: 0 buy · 8 sells. Total volume traded: €1.5m. History available since 1 June 2021. The latest transaction was filed on 3 July 2025 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations15 total
1,051 shares@ US$128.257.8% of flowCommon StockSEC:0001415889-25-019506:0
3,530 shares@ US$88.8020.0% of flowCommon StockSEC:0001415889-25-007375:0
11,000 shares0Common StockSEC:0001415889-25-006604:0
7,500 shares0Common StockSEC:0001415889-24-019391:0
4,000 shares@ US$105.1326.2% of flowCommon StockSEC:0001415889-24-015943:0
2,436 shares@ US$106.4316.1% of flowCommon StockSEC:0001415889-24-015540:0
2,286 shares@ US$90.6912.9% of flowCommon StockSEC:0001415889-24-007552:0
12,500 shares0Common StockSEC:0001415889-24-007009:0
2,307 shares@ US$52.067.6% of flowCommon StockSEC:0001415889-23-009403:0
736 shares@ US$45.722.1% of flowCommon StockSEC:0001415889-23-004560:0
12,500 shares0Common StockSEC:0001415889-23-004266:0
1,908 shares@ US$59.76100.0% of flowCommon StockSEC:0001415889-22-006308:0
8,750 shares0Common StockSEC:0001415889-22-002441:0
21,843 shares0Common StockSEC:0001179110-21-006329:0
21,843 shares0Common StockSEC:0001179110-21-006329
15 of 15 declarations
About Carter Percy H.
Percy H. Carter is the Chief Scientific Officer of Blueprint Medicines Corp. In this role, he oversees the company's research and development activities, focused on innovation in drug development. Blueprint Medicines is a biopharmaceutical company dedicated to discovering treatments for serious diseases. Percy H. Carter brings valuable scientific expertise, contributing to the advancement of the company's research.
